Patient P-01409

Synthetic patientNBL-101 · Day 112 · 35–44 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

72%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 47 SC-12 recommended — Supportive Compound SC-12
Day 48 Patient accepted — Started SC-12 in the companion
Day 52 GI-04 recommended — GI Support Protocol GI-04
Day 53 Patient accepted — Started GI-04 in the companion
Day 54 GI symptom burden −21% vs expected — Supportive Compound SC-12
Day 60 Tolerance state changed — Unstable → Improving
Day 61 No meaningful change — GI Support Protocol GI-04
Day 62 ME-01 recommended — Monitoring Escalation ME-01
Day 63 Patient accepted — Started ME-01 in the companion
Day 66 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

Toxicity-12
GI instability+4
Inflammatory activity+4
Nutritional resilience-4

What helped?

Supportive Compound SC-12Day 47
Result: symptom burden −21%
GI Support Protocol GI-04Day 52
Result: no meaningful change
Monitoring Escalation ME-01Day 62
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

63%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

55/100

improving · -4.4 vs previous 14 d

Toxicity

Blood

43.1/100

improving · -2.4 vs previous 14 d

Sleep quality

Wearable

21.5/100

stable · -0.9 vs previous 14 d

Energy level

Daily log

3/10

improving · +0.2 vs previous 14 d

Stress level

Daily log

7.6/10

improving · -0.4 vs previous 14 d

Steps

Wearable

3,186

improving · +158 vs previous 14 d

Adherence

Companion

50.1 %

stable · -0.8 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 26 from the failing basin, 61 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 77%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 77%

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep histamine low
GI +3.5 next day on high-intake days · n 14
Keep fat low
GI +2.5 next day on high-intake days · n 14

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+3.5detractor · 95%
Dietary fat load
+2.5detractor · 73%
Insoluble fibre
+2no signal · 46%
Alcohol
+1.9no signal · 47%
Spicy / capsaicin
+0.5no signal · 16%
Simple carbohydrates
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 55 and rising
Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 53
- WearableHRV 24 ms, trending down
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑40
- Wearable3,186 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 28 ms
Sleep: 6.3 h
Steps: 2,304
Resting HR: 68 bpm

Daily log: GI score 55, nutritional resilience 39, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01872	63%	S14	NP-02	improved	47
P-01834	60%	S14	NP-02	improved	44
P-01429	58%	S09	GI-04	improved	45
P-01332	57%	S14	NP-02	improved	43
P-01709	57%	S14	GI-04	improved	43
P-01462	56%	S14	NP-02	improved	47
P-01573	56%	S14	GI-04	improved	49
P-01496	55%	S14	SC-12	improved	46
P-01431	53%	S14	GI-04	improved	41
P-01775	53%	S14	SC-12	improved	48
P-01777	52%	S14	SC-12	improved	43
P-01656	51%	S14	ME-01	improved	41